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ScienceDirectMuscarinic receptor antagonists and b-adrenoceptor agonists
are used in the treatment of obstructive airway disease and
overactive bladder syndrome. Here we review the
pharmacological rationale for their combination. Muscarinic
receptors and b-adrenoceptors are physiological antagonists for
smooth muscle tone in airways and bladder. Muscarinic agonism
may attenuate b-adrenoceptor-mediated relaxation more than
other contractile stimuli. Chronic treatment with one drug class
may regulate expression of the target receptor but also that of the
opposing receptor. Prejunctional b2-adrenoceptors can enhance
neuronal acetylcholine release. Moreover, at least in the airways,
muscarinic receptors and b-adrenoceptors are expressed in
different locations, indicating that only a combined modulation of
both systems may cause dilatation along the entire bronchial tree.
Whileall of these factors contribute to a rationale for a combination
of muscarinic receptor antagonists and b-adrenoceptor agonists,
the full value of such combination as compared to monotherapy
can only be determined in clinical studies.
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Obstructive airway diseases such as asthma and chronic
obstructive pulmonary disease (COPD) and urinary
bladder dysfunction such as the overactive bladder syn-
drome (OAB) are typically seen as unrelated conditions.
However, both affect hollow organs and are characterized
by an imbalance between contractile and relaxant smooth
muscle stimuli. Moreover, the sympathetic and the para-
sympathetic nervous system plays important roles in both
cases, although sympathetic innervation may be sparse
[1]; accordingly muscarinic receptor antagonists and
b-adrenoceptor agonists are important therapeutics for
both organ systems. The present manuscript reviews
the molecular, cellular and tissue rationale underlying
the combined use of these two drug classes. We combine
data from airways and urinary bladder to improve the
robustness of emerging concepts.
Clinical background
COPD is a progressive disease associated mainly with
tobacco smoking, air pollution or occupational exposure,
which can cause obstruction of airflow in the lungs result-
ing in debilitating bouts of breathlessness. Inhaled
bronchodilators (b2 adrenoceptor agonists or M3 muscar-
inic acetylcholine receptor antagonists) remain the main-
stay of current management of COPD at all stages of the
disease [2]. Clinical advances in the treatment of COPD
have centered on improvements of these existing classes
of bronchodilators, by either increasing duration of action
or by improving their selectivity profiles [2]. The com-
bination of a b2-adrenoceptor agonist with a M3 muscar-
inic receptor antagonist, into a fixed-dose combination
therapy, is currently being pursued by several pharma-
ceutical companies.
The Global Initiative For Asthma defines asthma as a
‘chronic inflammatory disorder of the airways in which
many cells and cellular elements play a role’ (www.
ginasthma.org). In bronchi from asthmatic patients, con-
traction responses to muscarinic receptor agonists are
enhanced and relaxation responses to b-adrenoceptor
agonists are attenuated [3]. This airway hyperresponsive-
ness leads to recurrent episodes of wheezing, breathless-
ness, chest tightness, and coughing, particularly at night Commons Attribution-NonCommercial-No Derivative Works License,
edium, provided the original author and source are credited.
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associated with widespread, but variable, airflow obstruc-
tion within the lung that is often reversible either spon-
taneously or with treatment. First-line treatment of
asthma is based on low-to-medium doses of an inhaled
glucocorticoid, but this yields inadequate symptom con-
trol in many patients. Short-acting muscarinic receptor
antagonists and b-adrenoceptor agonists, often in combi-
nation, can be added as acute reliever medication. Long-
acting b-adrenoceptor agonists are an option as additional
controllers, but their safety when used as monotherapy
has been questioned. Alternative/additional controller
medications are needed [4] and the combination of a
long-acting b-adrenoceptor agonist with a long-acting
muscarinic antagonist is considered a possible option.
However, the efficacy and safety of such a combination,
or of monotherapy with a long-acting muscarinic antagon-
ist, has not been fully evaluated and hence is not an
approved use.
OAB is defined by the International Continence Society
by the presence of urgency, with or without incontinence,
usually accompanied by urinary frequency and nocturia
[5]. For a long time muscarinic receptor antagonists have
been the mainstay of OAB treatment [6], but recently
b3-adrenoceptor agonists are emerging as an alternative
treatment option [7,8]; the combined use of both drug
classes is currently undergoing clinical exploration.
Accordingly, COPD, asthma and OAB share a number of
features but also exhibit important differences [1]. The
most important one is that obstructive airway disease
leads to considerable morbidity and even mortality,
whereas OAB mainly adversely affects quality of life.
Nevertheless, it appears helpful to look at all three
conditions concomitantly as they share important features
with regard to the roles of the sympathetic and parasym-
pathetic system and its interaction. Such interaction can
occur at the level of exposure to the sympathetic and
parasympathetic mediators (which importantly includes
non-neuronal acetylcholine release in both airways and
bladder) and the level of smooth muscle tone.
Descriptive interaction studies between
muscarinic and b-adrenergic agents
Several studies have explored how concomitant exposure
to b-adrenergic and muscarinic receptor ligands affects
the response to each other. While there always is a
physiological antagonism between contractile and relax-
ant stimuli, it appears that this interaction is more pro-
nounced between relaxation by b-adrenoceptor agonist
and contraction by muscarinic receptor ligands than by
contracting agonists acting upon other types of receptors.
This section will describe the ‘privileged interaction’
between the b-adrenergic and muscarinic system in air-
ways and bladder. Subsequent sections will explore the
underlying mechanism for these interactions.Current Opinion in Pharmacology 2014, 16:31–42 Airway studies
Physiological resting tone in airways is mediated by
parasympathetic innervation of airway smooth muscle,
via muscarinic receptors. Muscarinic receptor subtypes
M2 and M3 are expressed at a 4:1 ratio [9] but the
contraction response is mediated predominantly if not
exclusively by the M3 subtype [10–12]. Regulation is
disturbed under pathological conditions [13,14]. In
addition to agonists of the muscarinic pathway, other
contractile mediators are released during pathological
conditions, including histamine and bradykinin, receptors
for which (H1 and B2, respectively) are located on airway
smooth muscle [15–17].
Airway smooth muscle relaxation is primarily mediated
by b-adrenoceptors, in humans and most other mammals
their b2-subtype [3,18]. This relaxation provides a phys-
iological antagonism of the contraction induced by
mediators such as carbachol and histamine. However,
there is a disparity between contractile agonists in their
ability to attenuate b2-adrenoceptor-mediated relaxation,
even when matched for initial extent of contraction. For
instance, the inhibitory potency of isoprenaline (pEC50)
to cause relaxation in canine airways was 8.0 against
histamine but only 7.0 against acetylcholine; even
100 mM isoprenaline did not fully reverse acetylcholine-
induced contraction [19]. The relative resistance of
muscarinic contraction to b2-adrenoceptor-induced relax-
ation was confirmed in human airway preparations [20–
22]. Whether the resistance to b2-adrenoceptor-mediated
relaxation was caused by activation of an M2 or M3
receptor has not been resolved conclusively [21,23,24]
but it may be mediated by PKC [25]. Thus, a privileged
interaction exists between b2-adrenoceptors mediating
relaxation and muscarinic receptors mediating contrac-
tion, whereby muscarinic receptor-induced contraction is
more resistant to b2-adrenoceptor induced relaxation,
than that induced by agonists acting independent of
muscarinic receptors. This may explain why combined
administration of a muscarinic antagonist and a b2-adre-
noceptor agonist causes greater airway relaxation than
monotherapy [26–30]. Moreover, while a long-acting
muscarinic antagonist had no significant effect by itself,
it enhanced the ability of a long-acting b2-agonist to
antagonize histamine-induced bronchoconstriction [31].
Moreover, in some of these studies combination treatment
not only reduced elevated smooth muscle tone but also had
greater anti-inflammatory effects than monotherapy.
Bladder studies
Muscarinic receptors are the primary mediator of urinary
bladder contraction during physiological voiding but, in
contrast to humans, non-cholinergic mediators can sig-
nificantly contribute to bladder contraction in the healthy
bladder of various animal species [32]. However, in both
animals and humans, non-cholinergic mediators such as
ATP or bradykinin become increasingly important underwww.sciencedirect.com
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Relaxation of rat bladder strips with passive tension or precontracted
with KCl, carbachol, bradykinin or serotonin by the b-adrenoceptor
agonist isoprenaline. Note that both the potency and the efficacy of
isoprenaline against carbachol were significantly smaller than against all
other conditions.
Taken from [44].pathological conditions [33–35]. Despite the much
greater expression of M2 than M3 receptors in the bladder
of humans and most other mammalian species (see ‘Re-
ceptor expression patterns in airways and bladder’ sec-
tion), the direct contractile effects of muscarinic agonists
is mediated primarily if not exclusively by the minor
population of M3 receptors [36]. The primary mediator
of bladder relaxation is b-adrenoceptors; in humans this
occurs primarily if not exclusively via the b3-subtype, but
in other species, for example, rats, additional subtypes
may be involved [37]. However, it should be noted that
the tone of detrusor smooth muscle is not only regulated
directly by autonomic receptors expressed by these cells
but also indirectly via muscarinic and b-adrenergic recep-
tors located on the urothelium and the afferent nerve
endings [38].
In porcine bladder and urethra the presence of isoprena-
line reduced the Emax and pEC50 of carbachol-induced
contraction [39,40]. In a follow-up study from the same
group isoprenaline caused parallel right-ward shifts of the
carbachol concentration–response curve but did not affect
maximum contraction; in urothelium-denuded bladder
strips isoprenaline caused greater right-ward shifts
than in the presence of urothelium, indicating that the
b-adrenoceptor agonist may in part act on the urothelium
[41]. In murine bladder isoprenaline reduced the potency
and efficacy of contractions by the muscarinic agonist
oxotremorine [24]. However, in M3 receptor knock-out
mice oxotremorine elicited only a small contractile
response, which was considerably enhanced in the pre-
sence of a,b-methylene ATP and isoprenaline, an effect
not observed in M2/M3 double knock-out mice [42].
The opposite experiment, that is, testing effects of a
muscarinic agonist on bladder relaxation by a b-adreno-
ceptor agonist, was largely performed in rats, a species
where relaxation involves not only b3-adrenoceptors but
also other subtypes [37]. Isoprenaline-induced relaxation
of rat bladder strips was less potent and less efficacious
against tone induced by carbachol than that induced by
KCl (pEC50 5.32 vs. 7.24, remaining tone 35% vs. full
relaxation) [43]. In another rat study relaxant responses to
isoprenaline were significantly less potent and less effi-
cacious against carbachol than against passive tension,
KCL, bradykinin or serotonin [44] (Figure 1). In a follow-
up study from the same group it was found that both M2
and M3 receptors contributed to the attenuation of the
isoprenaline response by muscarinic agonists [45]. Other
follow-up work from these investigators reported that
relaxation responses to the b3-selective agonist KUC-
7322 were also weaker against carbachol than against
the other responses (Cernecka, Sand and Michel; unpub-
lished observation). Another b3-selective agonist, TRK-
380, was less efficacious against carbachol than against
KCl in human detrusor strips [46]. Similarly, the phos-
phodiesterase inhibitor papaverine was less potent inwww.sciencedirect.com causing relaxation against carbachol- than against KCl-
induced tone in guinea pig [47], rat [48] and human
bladder [49]. Similarly, isoprenaline-induced relaxation
was enhanced in M2 receptor knock-out mice [24,42].
However, some conflicting data have been reported as
relaxation by a single high isoprenaline concentration was
similarly effective against KCl and carbachol-induced
contraction in canine bladder [50].
In conclusion most bladder data indicate that muscarinic
receptor agonists inhibit relaxation by b-adrenoceptor
agonists more than contractile stimuli acting independent
of muscarinic receptors. A stronger inhibition of b-adre-
noceptor responses by muscarinic agonists than by other
contractile stimuli has also been reported in esophagus
[51], ileum [24,52], colon [53] and the iris sphincter [54].
These findings support the concept of a privileged inter-
action between muscarinic and b-adrenergic pathways in
control of bladder smooth muscle tone and support the
combined use of a muscarinic antagonist and b-adreno-
ceptor agonist also in the bladder. In support of this
hypothesis the potency and efficacy of relaxant effects
of the b3-selective agonists CL 316,243, mirabegron and
solabegron in rat bladder against field stimulation was
enhanced in the presence of muscarinic receptor
antagonists [55].
Receptor expression patterns in airways and
bladder
The expression pattern of subtypes of muscarinic and
b-adrenergic receptors in airways and bladder has been
studied at the mRNA and protein level. While mRNACurrent Opinion in Pharmacology 2014, 16:31–42
34 Respiratorydetection techniques are unequivocal, their predictive
value for corresponding functional receptor protein
remains uncertain. Expression at the protein level can
be assessed using antibodies in immunoblot or immuno-
histochemistry studies, but most available receptor
antibodies lack suitable specificity [56]. It can also be
tested using radioligands in tissue homogenates or auto-
radiography; while this works well for b2-adrenoceptors,
radioligands for b3-adrenoceptors are just emerging [57]
and those for muscarinic receptors typically lack subtype-
selectivity. Despite these limitations, the combined
mRNA, protein and functional data allow a reasonably
clear picture on the expression of these receptors in
airways and bladder. Of note, expression in nerve term-
inals is typically not detected in most studies as they
represent only a minor fraction of the overall expression.
Airway studies
Muscarinic receptors are unevenly distributed in the
lung, exhibiting a greater expression in submucosal
glands and airway ganglia than in airway smooth muscle
[58]. The receptor present on smooth muscle from both
large and small airways was described as being entirely of
the M3 subtype in early studies, while the M1 receptor
was exclusively expressed in alveolar walls [9]. Recent
studies in human lung found the M3 receptor more
abundantly expressed in segmental than subsegmental
bronchus and entirely absent in the parenchyma, whereas
the M2 subtype was widely distributed throughout the
lung, and M1 was found only in parenchyma [59
].
Expression of lung b-adrenoceptors was also reported to
be higher in epithelium, alveolar walls and submucosal
glands than in airway and vascular smooth muscle [60].
The subtype responsible for labeling airway smooth
muscle was entirely b2, whereas co-expression of both
b1 and b2 was observed in bronchial submucosal glands
and alveolar walls, with the b1 subtype dominating, as also
confirmed in human lung [59]. Interestingly, the expres-
sion level of b2 increased along the airways, with levels
being lowest in the segmental bronchus and highest in the
parenchyma [59,60]. Thus, the relative roles of muscar-
inic and b-adrenergic receptors appear to differ, with the
former more prominent in the more proximal and the
latter in the more distal airway segments. Therefore,
maximal bronchodilation in all regions of the human lung
may require a combination of a muscarinic antagonist and
a b2-adrenoceptor agonist. Regulation of receptor expres-
sion in animal models of [61] and patients with obstructive
airway disease [62] may contribute to the pathophysiology
and treatment responses and may additionally support the
use of such combination treatment.
Bladder studies
Studies in whole human bladder have largely detected
mRNA for M2, M3 and M4 receptors and much less M1
expression [63]. This apparently applies similarly toCurrent Opinion in Pharmacology 2014, 16:31–42 smooth muscle [64] and urothelial cells [65,66]. Radioli-
gand binding studies confirm that muscarinic receptors in
the bladder of humans and animals largely belong to the
M2 subtype, with a smaller contribution of M3 and even
smaller one of other subtypes [67–69].
Studies in whole human bladder have reported that
b3-adrenoceptors contribute about 95% of total b-adre-
noceptor mRNA [70], whereas other subtypes may be
more prominently expressed in experimental animal
species such as rats [71]. Moreover, the relative contri-
bution of b-adrenoceptor subtypes at the mRNA level
may be different in human urothelium [66]. The relative
contribution of subtypes to total bladder b-adrenoceptor
expression at the protein level has been more difficult to
determine due to a lack of suitable radioligands or anti-
bodies [72], but some radioligand binding studies have
suggested that mostly b3-adrenoceptors may be present
[73]. On the basis of more recently emerging antibody
validation data [74], the presence of b3-adrenoceptors in
the human bladder has also been demonstrated by immu-
nohistochemistry, surprisingly showing an apparently
greater abundance in urothelium than in smooth muscle
[75,76]. Despite these uncertainties, there is overwhelm-
ing functional evidence that relaxation of human detrusor
smooth muscle occurs predominantly if not exclusively
via the b3-subtype, but in other species such as rats
additional subtypes may contribute [37].
Prejunctional modulation of transmitter
release
Smooth muscle tone is regulated by both the parasympa-
thetic and sympathetic nervous systems but the exact
contribution of each of these systems in maintaining tone
in physiology and disease is unclear in airways [77] and
bladder. Transmitter release from parasympathetic and
sympathetic nerve endings can be modulated by prejunc-
tional auto- and hetero-receptors, with M2 (and perhaps
M4) receptors typically inhibiting transmitter release from
both types of nerve terminals and M1 muscarinic and b2-
adrenergic receptors facilitating it [78]. Thus, prejunc-
tional receptors provide an additional level for an inter-
action between the two systems. Because of sparse
sympathetic innervation there has been limited attention
to modulation of noradrenaline release in airways [79] or
bladder [80], but several studies have explored the modu-
lation of neuronal acetylcholine release. As in many other
tissues, acetylcholine release can also come from non-
neuronal sources in airways [81] and bladder [82]. While
such non-neuronal release is considered important,
particularly in disease, little is known about its regulation
by muscarinic or b-adrenergic receptors; hence it will not
be discussed here.
In the airways direct assessment of b-adrenoceptor
effects on acetylcholine release has yielded conflicting
results. The facilitation of transmitter release bywww.sciencedirect.com
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strated for the heteroreceptors on parasympathetic
nerves in equine [83,84] and guinea pig airways [85];
in one of these studies, however, such facilitation was
only detectable when inhibitory muscarinic autorecep-
tors were blocked [84]. In contrast, inhibition of acetyl-
choline release by b-adrenoceptor agonists was observed
in rat and guinea pig [86] and in bovine airways [87].
Except for the inhibition in rat (apparently b1-adreno-
ceptor-mediated), all facilitating and inhibitory effects
on acetylcholine release were b2-mediated.
Indirect evidence in this regard comes from studies in
which the inhibition of airway contraction induced by
either electrical field stimulation of exogenously applied
acetylcholine was compared. Isoprenaline and several
b2-adrenoceptor agonists inhibited the response to field
stimulation more potently and/or effectively than that to
acetylcholine in equine [83,84] and human airways
[88,89]. On the other hand, isoprenaline was similarly
potent against both contractile stimuli in guinea pig
trachea [85]. Interestingly, the inhibition of acetylcholine
release may involve not only cAMP but also BKCa [87].
Thus, the functional role of prejunctional b-adrenocep-
tors on parasympathetic nerves in the airways has not yet
been fully resolved. Species differences are possible but
technical differences in the preparations being employed
may also have contributed, particularly blockade of
muscarinic autoreceptors or presence of functional epi-
thelium [85,87]. Nevertheless, it has been argued that both
the facilitatory and the inhibitory effect would be in favor
of combining a muscarinic antagonist and a b2-agonist [90].
If it is facilitatory, the muscarinic antagonist will overcome
the mitigation of direct smooth muscle effects of b-agonist;
if it is inhibitory, the combined effect at the smooth muscle
effect will be stronger than either agent alone.
Studies in the bladder have not focused on b-adrenocep-
tors but rather on muscarinic autoreceptors regulating
acetylcholine release. Irrespective of the use of direct
measurements of acetylcholine release or of modulation
of contraction induced by field stimulation, these studies
have unequivocally demonstrated a role for facilitatory
M1 receptors and inhibitory M2 and M4 receptors in rat
[63,91–93], mouse [42], rabbit [94] and human bladder
[95]. As the non-subtype-selective atropine enhanced
acetylcholine release in several of those studies, the
net effect of the various muscarinic autoreceptors appears
to be inhibitory. This may limit the usefulness of a
muscarinic antagonist (unless it has very low M1 affinity)
and further supports the concept of combination treat-
ment with a b-adrenoceptor agonist.
Intra-cellular signaling cross-talk
The prototypical primary signaling pathway of M2 and M3
muscarinic receptors is inhibition of adenylyl cyclase and
stimulation of phospholipase C (PLC), respectively, thewww.sciencedirect.com latter leading to formation of inositol phosphates and
diacylglycerol, which in turn mobilize Ca2+ from intra-
cellular stores and activate protein kinase C (PKC),
respectively [96]. Additionally, coupling to a phospho-
lipase D and, as a downstream event of all of the above,
myosin light chain phosphorylation and activation of rho
kinase have been demonstrated. Given the role of Ca2+ in
initiating smooth muscle contraction, it seems plausible
that the PLC activation is the molecular basis of muscar-
inic receptor mediated smooth muscle contraction in
airways and bladder, but this view has been challenged.
The prototypical signaling pathway of all b-adrenoceptor
subtypes is stimulation of adenylyl cyclase leading to
formation of cAMP, which can activate protein kinase A
(PKA) [97]. More recently it became clear that cAMP may
alternatively also activate the exchange protein activated
by cAMP (Epac) pathway [98]. While various cAMP-
elevating agents such as the direct adenylyl cyclase acti-
vator forskolin or phosphodiesterase inhibitors can induce
airway and bladder relaxation, many studies have ques-
tioned whether cAMP formation indeed underlies relaxa-
tion induced by b-adrenoceptor agonists. Moreover,
b-adrenoceptors can couple to activation of several potass-
ium channels, mostly large conductance, Ca2+-activated
channels (BKCa). An overview on the signal transduction
pathways of muscarinic and b-adrenergic receptors in
smooth muscle cells is shown in Figure 2.
Airway studies
While the involvement of PLC and PKC in muscarinic
receptor-mediated airway contraction is plausible, there is
only little experimental proof. However, in its support
PKC inhibition enhanced the ability of methacholine to
contract bovine trachea [25].
b-Adrenoceptor agonist-induced smooth muscle relaxa-
tion in airways involves activation of potassium channels,
mostly BKCa channels [99]. Activation of such channels
and relaxation may involve partly cAMP/PKA-dependent
and partly cAMP-independent pathways in airways
[100,101], possibly involving direct coupling of b-adre-
noceptor-activated Gsa to BKCa [100].
Several studies have explored how b-adrenoceptor acti-
vation affects contraction-relevant signaling by muscar-
inic receptors in the airways (corresponding bladder data
are largely lacking). Whether b-adrenoceptor agonists and
other cAMP-elevating or mimicking agents suppress
muscarinic receptor-mediated inositol phosphate for-
mation has remained controversial. Lack of inhibition
was reported by some investigators in canine [102] or
bovine tracheal smooth muscle [15,103], but inhibition
was observed in porcine [104] and canine tracheal smooth
muscle by others [105,106]; interestingly, the inhibition at
the 24 hours time point in the dog study was abolished by
the protein synthesis inhibitor cycloheximide.Current Opinion in Pharmacology 2014, 16:31–42
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Schematic representation of assumed signal transduction pathways involved in the regulation of smooth muscle contraction by muscarinic and
b-adrenergic pathways. AC, adenylyl cyclase; AR, adrenoceptor; DAG, diacylglycerol; IP3, inositol-tris-phosphate; MLC, myosin light chain; PKA,
protein kinase A; PKC, protein kinase C; PLC, phospholipase C; PLD, phospholipase D; SR, sarcoplasmic reticulum. Red and green lines and arrows
represent pathways activated by muscarinic and b-adrenergic receptors, respectively.On the other hand, inhibition of muscarinic agonist-
induced intracellular Ca2+ elevation in airway smooth
muscle by b-adrenoceptor agonists or other cAMP-related
agents was consistently observed in bovine [103,107],
porcine [108], murine [109] and canine preparations
[105,110], although it was reported to wane over time
in the latter [106]. Several mechanisms have been pro-
posed how b-adrenoceptor agonists may attenuate Ca2+
elevations: firstly, cAMP/PKA-mediated inhibition of
L-type Ca2+ channels [111]; secondly, reductions of
Ca2+ oscillations [108,112], which have been linked to
reducing Ca2+ release from internal stores under control
of inositol phosphate receptors [109]; thirdly, activation of
the sarcoplasmatic reticulum Ca-ATPase (SERCA) [18];
fourthly, reduction of the detectable number of inositol-
1,4,5-trisphosphate binding sites [113]. Moreover, b-adre-
noceptor stimulation apparently reduces not only Ca2+
elevations but also the Ca2+ sensitization of contractile
filaments induced by muscarinic agonists [114] or
histamine [112]. On the other hand, in contrast to most
other cell types, b-adrenoceptor agonists not only sup-
press Ca2+ elevations or lower basal Ca2+ concentrationsCurrent Opinion in Pharmacology 2014, 16:31–42 [115] but at least in some cases can also increase it in
airway smooth muscle cells [107] and this effect may
differ between subcellular compartments [116]. Similarly,
they can both activate phospholipase D in porcine tra-
cheal smooth muscle and inhibit such activation caused
by muscarinic stimulation [104]. However, it remains
difficult to understand how b-adrenoceptor-mediated
Ca2+ elevations or phospholipase D activation can be
related to smooth muscle relaxation, unless they are
restricted to subcellular compartments not linked to
the contractile machinery.
Other studies have explored how muscarinic receptor
activation affects relaxation-relevant signaling by
b-adrenoceptors. Although direct contractile effects of
muscarinic stimulation occur almost exclusively via the
M3 subtype, attenuation of relaxation involves both M2
and M3 receptors based on knock-out mouse data [24].
Muscarinic receptor-mediated inhibition of cAMP
accumulation is a bona fide M2 response and well docu-
mented in airway smooth muscle [117–119]. Additional
evidence comes from experiments in bovine airwaywww.sciencedirect.com
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Epac as a novel effector of airway smooth muscle relaxation. Cumulative
concentration response curves of the selective Epac activators 8-pCPT-
2’-O-Me-cAMP (8-pCPT) and Sp-8-pCPT-20-O-Me-cAMPS on
methacholine (0.3 mM) precontracted guinea pig tracheal open ring
preparations in the absence (control) or presence of 100 mM of the
selective protein kinase A inhibitor Rp-8-CPT-cAMPS. Results are
means  SEM of 3-8 independent experiments. Stress fiber formation
was measured by phalloidin staining in guinea pig airway smooth
muscle. Results are expressed as percentage of stress fiber-positive
cells relative to the total number of cells. Representative images of 5
experiments are shown. These data demonstrate that cAMP generated
upon b-adrenoceptor stimulation may relax airway smooth muscle via
the Epac pathway.
Taken from [123].smooth muscle where isoprenaline or the cAMP-mimetic
8-bromo-cAMP lowered basal Ca2+ concentration; car-
bachol abolished such lowering but did not affect Ca2+
lowering by release of caged cAMP, indirectly indicating
that this interaction occurred through inhibition of ade-
nylyl cyclase by muscarinic receptors [115]. While an
obvious explanation for adenylyl cyclase inhibition is an
effect mediated by M2 receptors acting via Gi, M3 recep-
tors may also be involved. Elevation of Ca2+ inhibited
isoprenaline-stimulated adenylyl cyclase in human bron-
chial smooth muscle cells, apparently acting on the
cyclase isoform AC6 which was also shown to colocalize
with b2-adrenoceptors [120].
Although K+ channels, specifically BKCa critically con-
tribute to b-adrenoceptor-mediated airway smooth
muscle relaxation, muscarinic modulation of such acti-
vation has received only limited attention. While it would
be expected that BKCa inhibition if anything should
enhance smooth muscle contractility, the opposite was
found in BKCa knock-out carbachol-contracted murine
airways [121]. Concomitantly, relaxation responses to
isoprenaline were enhanced. This paradoxical effect
reduction of muscarinic and enhancement of b-adrener-
gic responses in BKCa knock-out mice was explained by a
compensatory upregulation of the cGMP pathway.
Some studies have explored how muscarinic and b-adre-
nergic pathways interact at the level of the contractile
machinery. In an early study in canine trachea it was
found that forskolin raised cAMP levels and myosin light
chain kinase phosphorylation but lowered myosin phos-
phorylation; in contrast, methacholine caused myosin
phosphorylation but did not significantly affect cAMP
content or myosin light chain kinase phosphorylation;
when forskolin was added to methacholine, relaxation
occurred which was accompanied by a lowered cAMP
content, some reduction of myosin phosphorylation but
no change in myosin light chain kinase phosphorylation
[119]. Myosin light chain phosphatase activity was
increased by isoprenaline in bovine tracheal smooth
muscle, whereas carbachol lowered basal and isoprena-
line-stimulated phosphorylation [18]. Activation of rho
and rho kinase may link the proximal signaling of muscar-
inic receptors to changes in myosin light chain kinase
activity. The carbachol-induced activation of rho and rho
kinase in bovine trachea was not affected by pretreatment
with isoprenaline or salmeterol, but adding the b-adre-
noceptor agonist after carbachol reduced activities of rho,
rho kinase, myosin light chain kinase and also reduced
contractile tone [122]; these findings were interpreted as
indication that some interaction between the muscarinic
and b-adrenoceptor pathways can occur at the rho and rho
kinase level, but the major part may occur at the myosin
light chain kinase level. Experiments in guinea pig and
human airways demonstrated that cAMP may cause re-
laxation of methacholine-contracted airways not only viawww.sciencedirect.com the PKA but also via the Epac pathway [123] (Figure 3).
Epac activation reduced methacholine-induced rho A
activation and Rac1 inhibition and also myosin light chain
phosphorylation.
Bladder studies
The muscarinic receptor subtypes involved in attenuation
of b-adrenoceptor-mediated bladder relaxation have been
studied based on pharmacological inhibitors [45] and
muscarinic subtype knock-out mice [24,42]. Both
approaches have shown that, similar to airways, direct
contractile effects of muscarinic stimulation occur almost
exclusively via the M3 subtype, but attenuation of relaxa-
tion involves both M2 and M3 receptors. The M3 com-
ponent of such attenuation was blocked by inhibition of
PLC or PKC [45], both of which had not attenuated M3-
mediated direct contractile responses in the bladder [124].
Surprisingly, multiple studies in rat, mouse and human
bladder have demonstrated that muscarinic agonists
induce contraction largely independent of PLC and
rather rely on the opening of L-type Ca2+-channels andCurrent Opinion in Pharmacology 2014, 16:31–42
38 Respiratorythe activation of rho kinase, indicating that influx of
extracellular Ca2+ through such channels and Ca2+ sen-
sitization of contractile filaments may be more important
than mobilization of Ca2+ from intracellular stores [124].
However, it should be noted that muscarinic receptor
stimulation can not only directly cause smooth muscle
contraction, largely via the M3 subtype, but can also
attenuate b-adrenoceptor-mediated relaxation, at least
partly via the M2 subtype, and that the latter may involve
at least partly distinct signaling pathways.
Although b-adrenoceptor agonists stimulate cAMP for-
mation in the bladder, cAMP appears to play only a minor
if any role in bladder relaxation mediated by these
receptors [124]. Whether muscarinic receptors mediate
inhibition of cAMP accumulation in the bladder has
remained controversial [68,125].
On the other hand, similar to the airways, the b-adreno-
ceptor agonist-induced smooth muscle relaxation in blad-
der involves activation of potassium channels, mostly BKCa
channels [124,126]. However, muscarinic modulation of
such activation has received only limited attention. In mice
with either constitutive or smooth muscle-specific induci-
ble BKCa knock-out bladder contractions elicited by elec-
trical field stimulation, a response largely mediated by
muscarinic receptors, were enhanced [127]. This was
accompanied by an enhanced suppression of such contrac-
tions by a b-adrenoceptor agonist. Interestingly, this sup-
pression was more pronounced in the inducible than the
constitutive knock-out, apparently reflecting reduced
L-type Ca2+ current density and increased expression of
cAMP-dependent protein kinase in the constitutive
knock-outs. Collectively, these data demonstrate that
muscarinic and b-adrenergic signaling opposes each other
at multiple levels of their signaling cascade; however, they
also illustrate that the molecular mechanisms underlying
such interaction may differ between airways and bladder.
Chronic cross-regulation of receptor
expression and desensitization
A key feature of long-term administration of receptor
agonists and antagonists is that they may cause desensi-
tization and sensitization, respectively, of their cognate
receptors. Perhaps more importantly in the present con-
text, chronic activation of one receptor may also affect the
function of a physiologically opposing receptor. Such cross-
regulation has extensively been studied in the heart, largely
representing M2 and b1 subtypes [128
], but due to invol-
vement of different receptors subtypes and physiological
differences between cardiomyocytes and smooth muscle
cells these cardiac findings have limited applicability to
airways and bladder and will not be considered here.
Studies with extended exposure to agonists in airways and
bladder have reported both sensitization and attenuation
of the opposing pathway. An early study reported thatCurrent Opinion in Pharmacology 2014, 16:31–42 a 28-day treatment of rabbits with albuterol enhanced
the in vitro contractile response of main bronchi to
methacholine [129]; as KCl responses were not altered,
these findings already pointed to a specific interaction
with the muscarinic receptors and their signaling. Pro-
longed b-agonist exposure may also sensitize the function
of other pro-contractile receptors in the airways, for
example, bradykinin or histamine receptors [130,131].
This concept has been further explored using mice which
either lacked b2-adrenoceptors or overexpressed them
[132]; the former exhibited a reduced bronchoconstrictor
response to methacholine and other agents, whereas the
latter had an increased response, and both findings were
related to a reduced or enhanced expression of PLC-b1.
The intracellular Ca2+-handling protein phospholamban
was also identified as a target explaining increased
bronchoconstrictor sensitivity upon b2-adrenoceptor
overexpression [133]. Using a similar approach, these
investigators also explored consequences of overexpres-
sion of the G-protein Gia2, which mediates signals of M2
muscarinic receptors, or of a peptide inhibitor of this G-
protein [134]; as expected, overexpression of Gia2 atte-
nuated bronchodilator responses to b2-adrenoceptor ago-
nists while inhibition enhanced them. On the other hand,
overexpression of Gia2 unexpectedly decreased contrac-
tile response to methacholine, whereas its inhibition
enhanced them. The former was linked to a reduced
PLC and the latter to an increased PKCa expression. A
PKC activator was found to enhance agonist-induced
desensitization of b2-adrenoceptor function in bovine
airways [135]. Much less data is available for the urinary
bladder, but one recent study reported shown that rat
bladder b-adrenoceptors can desensitize upon prolonged
exposure to some agonists, which is accompanied by a
reduced contractile response to carbachol [136]. Taken
together, these data show that chronic activation of one
pathway may have effects on the opposing pathway, but
the direction of such cross-regulation may differ among
experimental models and also from the interaction seen
upon acute agonist administration.
Conclusions and clinical implications
The above data demonstrate that the muscarinic and
b-adrenergic systems in airways and bladder oppose each
other at multiple levels, including mediator release,
receptor signal transduction and receptor regulation, all
funneling into functional antagonism at the level of
smooth muscle tone. While there are distinct differences
between airways and bladder in these interactions, both
organs have pathologies characterized by too much
muscarinic and too little b-adrenergic input. Therefore,
the above data support the concept of combining muscar-
inic receptor antagonists and b-adrenoceptor agonists in
obstructive airway disease and OAB. While such combi-
nations have long been part of medical practice for
short-acting drugs in obstructive airway disease and
are guideline-recommended (www.ginasthma.org), thewww.sciencedirect.com
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b-adrenoceptor agonists is currently undergoing clinical
investigation [90]. Actually, such combinations may not
only have beneficial direct effects on airway smooth
muscle tone but also on airway inflammation [137]. Less
evidence for the use of such combinations is available for
OAB treatment [55], but some clinical studies have been
completed and are awaiting reporting (SYMPHONY
study NCT01340027) or are ongoing. In both therapeutic
areas additional clinical studies will be required to fully
understand the role of combination treatment, particu-
larly with regard to the use of long-acting compounds and
long-term treatment outcomes.
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